Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• Amundi more than doubled its Elanco stake in the first quarter, owning 98,313 shares valued at approximately $2.35 million. Institutional investors collectively hold 97.48% of ELAN’s outstanding stock.
• Elanco reported stronger-than-expected quarterly results, with adjusted EPS of $0.34 versus the $0.27 estimate and revenue up 10.2% year over year to $1.37 billion. The company also raised its full-year 2026 earnings, revenue and EBITDA guidance.
• Analyst sentiment remains positive, with UBS and KeyCorp raising their price targets; the stock has a “Moderate Buy” consensus rating and an average target of $29.09 versus its recent $24.23 price.

Amundi lifted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 101.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 98,313 shares of the company's stock after buying an additional 49,608 shares during the quarter. Amundi's holdings in Elanco Animal Health were worth $2,353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Elanco Animal Health in the first quarter valued at approximately $2,065,000. Goldman Sachs Group Inc. lifted its holdings in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Empowered Funds LLC lifted its holdings in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock worth $166,000 after buying an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after buying an additional 76,408 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company's stock valued at $4,432,000 after buying an additional 295,651 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Down 7.6%

Shares of NYSE ELAN opened at $24.23 on Friday. Elanco Animal Health Incorporated has a 52-week low of $15.50 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The stock has a market cap of $12.10 billion, a P/E ratio of -59.09, a P/E/G ratio of 1.73 and a beta of 1.67. The firm has a 50 day moving average price of $24.73 and a 200 day moving average price of $24.10.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.12%. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.1 EPS for the current year.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco beat estimates with second-quarter adjusted EPS of $0.34 versus the $0.27 consensus, while revenue rose 10.2% year over year to $1.368 billion, exceeding estimates of $1.31 billion. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $1.10-$1.16 from prior expectations near $1.07, increased revenue guidance to $5.09-$5.14 billion, and lifted its adjusted EBITDA forecast to $1.01-$1.035 billion. It also raised its innovation-revenue target to $1.25 billion. Elanco Lifts Outlook as 2Q Profit, Revenue Rise
• Positive Sentiment: Management cited continued momentum in newer products, with allergy treatment Zenrelia reaching blockbuster status. CEO Jeff Simmons also pointed to increased tick-bite activity and ongoing consumer spending on pet-health products as supportive demand trends. Elanco CEO on Boosted Forecast, Surge in Tick Bites
• Positive Sentiment: Analyst sentiment improved after the earnings report: UBS raised its price target from $31 to $33 and assigned a Buy rating, while KeyCorp increased its target from $29 to $30 and maintained an Overweight rating.
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion. The EPS range is broadly in line with consensus, so it offers limited near-term upside relative to the stronger full-year outlook.
• Negative Sentiment: Elanco remains leveraged, although management improved its year-end net-leverage target to approximately 3.0 times adjusted EBITDA from 3.1 times at the end of the second quarter. Reported net income was $54 million, and the company continues to post a negative reported net margin.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the company's stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider owned 160,812 shares of the company's stock, valued at $3,272,524.20. This represents a 3.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company's stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research reports. KeyCorp lifted their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday. UBS Group upped their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday. Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 22nd. Finally, TD Cowen boosted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source